Category: Downsizing

Sandoz closes generic development center in India 
Posted on Dec 05, 2012

Last week, Sandoz announced they are closing a number of generic product development centers around the world, including the Sandoz Development Centre near Mumbai. A few items in this report caught our eye. First, this hat tip to the CRO industry: While a pharma industry expert said the closure of the development centre would mean

Observations from AAPS in Chicago 
Posted on Oct 23, 2012

We spent a few days in Chicago attending the AAPS Convention. As usual, it was jammed with excellent science, tons of exhibitors, and great opportunities to catch up with old friends. The Tuesday evening “sessions” were especially enlightening. Here are a few random observations, based on our admittedly limited (2-day) participation: There are a LOT

Sandwich Shoppe Sold 
Posted on Aug 07, 2012

On Friday, it was announced that the former Pfizer R&D center in Kent, UK, was sold: The new agreement with Discovery Park will see the consortium take over 297 acres of offices, laboratories, warehouses and parkland, while Pfizer will retain some operations having taken out a lease for some sections of the Park. We see

Insourcing: A new outsourcing approach? 
Posted on Nov 09, 2011

Pharmaceutical outsourcing to CROs is certainly nothing new. However, this week we learned that pharmaceutical giant Lilly and AMRI signed an interesting insourcing / outsourcing agreement. In this deal, AMRI will hire 40 chemists to work on Lilly projects. However, these chemists will not work in Albany or in any of the other AMRI facilities

Incubating a biotech future for tomorrow 
Posted on Aug 22, 2011

On the one hand, you hate to see talent leaving the US. But, you have to applaud their attitude: “Although we are comfortable in America, we often felt that something was missing,” says YeXin, Duan’s partner in the venture. “The missing piece is a sense of achievement. Though we were well paid at the American

Merck Cuts 
Posted on Aug 01, 2011

As we were wrapping up our annual July vacation, we were¬†shocked¬†to hear about the magnitude of job cuts at Merck. This is on top of the 11,500 jobs Merck cut last year. Even worse, Merck apparently intends to trim headcount to their pre-Shering-Plough days, which translates into (roughly) an additional 41,000 jobs (91,000 currently –

Google Plus   Facebook   Twitter
Powered By : Supra International Inc.